FLAURA is a phase III trial pitting the third-generation EGFR–tyrosine kinase inhibitor osimertinib against gefitinib or erlotinib for the first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer.
The previously reported progression-free survival results have led to first-line approvals in the USA, Europe, and elsewhere, and osimertinib has become the preferred front-line option in this setting.
The overall survival data were reported at the ESMO Congress 2019, showing an overall survival boost for advanced NSCLC patients with osimertinib.
Suresh Ramalingam presents the overall survival analysis of the FLAURA trial, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).